Results 201 to 210 of about 785,737 (289)

Cleavage‐Resistant CYLD Protects Against Autoimmune Hepatitis

open access: yesAdvanced Science, EarlyView.
Proteolytic cleavage of the deubiquitinase CYLD emerges as a critical driver of autoimmune hepatitis. TNFα‐induced CYLD loss in macrophages amplifies S100A9‐triggered MAPK activation, leading to excessive chemokine production and hepatic inflammation. Pharmacological inhibition of MEK signaling effectively attenuates experimental disease, highlighting ...
Han Liu   +13 more
wiley   +1 more source

ERM Inhibition Confers Ferroptosis Resistance through ROS‐Induced NRF2 Signaling

open access: yesAdvanced Science, EarlyView.
ERM inhibition disrupts ERM‐actin interactions, elevating ROS and triggering KEAP1 degradation, which stabilizes and activates NRF2. Nuclear NRF2 induces cytoprotective genes, notably HMOX1, enhancing redox buffering and suppressing lipid peroxidation to resist erastin‐induced ferroptosis.
Menghao Qiao   +19 more
wiley   +1 more source

HSP70 Interactome‐Mediated Proteolysis Targeting Chimera (HSP70‐PROTAC) for Ferroptosis‐Driven Cancer Treatment

open access: yesAdvanced Science, EarlyView.
This study reports a novel targeted protein degradation strategy termed “HSP70‐PROTAC” that recruits Hsc70 complex to a target protein for inducing degradation. Among them, GDAz‐3 exhibits effective GPX4 degradation activity via UPS/CMA processes, triggering ferroptosis‐driven anticancer activity in vitro and in vivo.
Jinyun Dong   +15 more
wiley   +1 more source

DNA Nanostructure‐Templated Multivalency Enables Broad‐Spectrum Virus Inhibition

open access: yesAdvanced Science, EarlyView.
A honeycomb‐shaped DNA nanostructure is introduced that organizes nanobodies or aptamers into trimeric clusters mirroring the native hemagglutinin arrangement on influenza viruses. This geometry‐matched multivalency enhances binding avidity by up to 1000‐fold, resulting in robust, broad‐spectrum viral neutralization and a 30–55% improvement in host ...
Saurabh Umrao   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy